On October 16, 2017 Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported that it will report preclinical data supporting the clinical development strategy for its Chk1 inhibitor, SRA737, in a poster to be presented at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held from October 26 – 30, 2017 in Philadelphia, Pennsylvania (Press release, Sierra Oncology, OCT 16, 2017, View Source [SID1234520968]). SRA737 is currently being investigated in two Phase 1 clinical trials in patients with advanced cancers; as a monotherapy, and in combination with low-dose gemcitabine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Know more, wherever you are:
Latest on AACR (Free AACR Whitepaper)-NCI-EORTC through 1stOncology, book your free 1stOncology demo here.
Title: The Chk1 inhibitor, SRA737, demonstrates chemical synthetic lethality with replication stress-inducing agents, including novel low-dose gemcitabine, in preclinical models of cancer.
Poster #181; Abstract #B181:
Session: Poster Session B; Therapeutic Agents: Small-Molecule Kinase Inhibitors
Date and Time: Sunday, October 29, 2017, 12:30 PM – 4:00 PM
Location: Hall E, Pennsylvania Convention Center
The Poster will be available October 29, 2017 on the company’s website at www.sierraoncology.com.